Skip navigation

Prioritize and Proactively Manage Emerging Areas of Risk

February 27-28, 2019
  • Philadelphia, PA

At CBI’s 7th Annual Compliance Monitoring Congress, leading industry experts convene to discuss the challenges of expanding compliance monitoring efforts to address growing areas of risk with limited resources.

  • Develop a proactive compliance monitoring strategy —
    Explore how to select key areas of risk to focus on and what key stakeholders should help drive the plan
  • Implement data analytics to ensure end-to-end risk mitigation — Deploy data analytics for risk identification, case tracking and remediation
  • Determine the optimal structure, size and skillset of your compliance monitoring team —
    Ensure the right structure to stay relevant and risk-based
  • Examine the value of embedding compliance partners into the businesses —
    Identify strategies to help your business partners “own” compliance
  • Explore tools and processes to automate compliance monitoring efforts
  • Mitigate risk in interactions with patient support programs and specialty pharmacies
  • Deploy effective strategies to manage Anti-Bribery and Anti-Corruption Risk with third party vendors —
    Engage data driven monitoring to manage third-party risk
  • Understand compliance monitoring trends for emerging risk areas — Patient support programs, social media, clinical research organizations and nurse educator programs
  • Consider global compliance monitoring trends and best practices

Previous Attendee Acclaim:

Compliance Monitoring is a great way to learn best practices and network. I’ll be back next year.

Global Publication Planning Monitor, Bristol-Myers Squibb

This is a great opportunity to learn tangible monitoring strategies no matter what phase your monitoring program is in.

Director, Oversight and Monitoring, Johnson & Johnson

A great way to learn more about monitoring and to
meet monitoring peers in other organizations.

Lead analyst, MD Monitoring, Johnson & Johnson

CBI created an excellent program at the Monitoring conference in February with so many relevant topics in this crucial area for Biopharma firms. We had some really great conversations on the current and futurestate of Monitoring.

Managing Director, Helio Health Group